OABI OmniAb, Inc.
USHealthcareAs of 2026-07-09 12:34
Why OABI matters now
OmniAb, Inc. (OABI) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.27 with -1.52% on the session and $269.7M in market capitalization; recent performance reads 1-month -1.27% and YTD +26.49%.
The latest financial table shown here is Q1 2026, with revenue of $14.4M, net income of $-7.7M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.3%.
The latest indexable market news headline is "OmniAb Q1 Earnings Call Highlights" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes Love Steven filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.14
P/S
9.64
EV/EBITDA
-7.96
DCF Value
$-0.28
FCF Yield
-9.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
35.5%
Operating Margin
-200.3%
Net Margin
-187.7%
ROE
-20.3%
ROA
-18.5%
ROIC
-20.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.4M | $-7.7M | $-0.06 |
| Q4 2025 | $8.4M | $-14.2M | $-0.11 |
| FY 2025 | $18.7M | $-64.8M | $-0.57 |
| Q3 2025 | $2.2M | $-16.5M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.15
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.